Bavencio OverviewAvelumab (MSB0010718C) is a fully human monoclonal PD-L1 antibody of isotype IgG1, currently in development by Merck KGaA, Darmstadt, Germany & Pfizer for use in immunotherapy, especially for treatment of Non-small-cell lung carcinoma (NSCLC) . Approved by US FDA in 2017 for Merkel cell carcinoma. Contents 1 Mechanism of action 2 Clinical trials 3 Approvals and indications 3.1 Merkel-cell carcinoma 4 See also 5 References Mechanism of action Avelumab binds to the PD liga...
Read more Bavencio Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Avelumab
Recent Bavencio Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 20mg/ml
NDC Database Records for Bavencio: (1 result)Sorted by National Drug Code
- 44087-3535 Bavencio 20 mg/ml Intravenous Injection, Solution, Concentrate by Emd Serono, Inc.